Form 4: Athira Pharma Chief Scientific Officer Reports Significant Equity Transactions

Athira Pharma's Chief Scientific Officer, Kevin Church, reported recent acquisitions of common stock through the company's Employee Stock Purchase Plan and Restricted Stock Unit vesting, alongside a non-discretionary sale to cover tax obligations.

Summary

• Kevin Church, Chief Scientific Officer of Athira Pharma, Inc. (ATHA), reported changes in his beneficial ownership of common stock.
• On May 19, 2025, 10,000 shares of common stock were acquired at a price of $0.2312 per share through the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP). These shares were purchased at 85% of the closing price on that date.
• On June 30, 2025, 36,666 shares of common stock were acquired upon the vesting of Restricted Stock Units (RSUs) at a price of $0.
• On July 1, 2025, 8,526 shares of common stock were sold at a weighted-average price of $0.2935 per share to cover tax withholding obligations related to the RSU vesting. The shares were sold in a price range of $0.2854 to $0.3031.
• Following these transactions, Kevin Church's direct beneficial ownership of common stock is 168,901 shares.
• An additional 36,667 Restricted Stock Units remain beneficially owned, which convert to common stock on a one-for-one basis.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the insider's continued participation in equity plans and acquisition of shares, balanced by a non-discretionary sale for tax purposes, which is a routine event and does not indicate a lack of confidence.

Positives

• Acquisition of 10,000 shares through the Employee Stock Purchase Plan (ESPP) at a discounted price of $0.2312, demonstrating continued participation in company equity programs.
• Vesting of 36,666 Restricted Stock Units (RSUs) on June 30, 2025, increasing the Chief Scientific Officer's direct beneficial ownership of common stock.
• The RSU vesting and ESPP purchase indicate the Chief Scientific Officer's ongoing equity stake and alignment with shareholder interests.

Negatives

• A sale of 8,526 shares of common stock occurred on July 1, 2025, reducing the direct beneficial ownership, although this was a non-discretionary 'sell to cover' transaction for tax withholding.

Risks

• No specific new risks are introduced by this Form 4 filing. The transactions reflect routine equity compensation and tax obligations for an insider.

Future Outlook

The Chief Scientific Officer has 36,667 Restricted Stock Units remaining, with the final one-third scheduled to vest on December 31, 2025, subject to continued service.

Management Comments

• The acquisition of shares through the Employee Stock Purchase Plan (ESPP) was a voluntary report, exempt under Rule 16b-3(c).
• The sale of shares on July 1, 2025, represents shares sold to cover tax withholding and remittance obligations in connection with the vesting of restricted stock units, and does not represent a discretionary sale.

Industry Context

This Form 4 filing details routine insider equity transactions for Athira Pharma, Inc.'s Chief Scientific Officer. Such filings are common across all industries for publicly traded companies, reflecting standard executive compensation practices involving stock-based incentives.

Comparison to Industry Standards

• The use of Employee Stock Purchase Plans (ESPPs) and Restricted Stock Units (RSUs) as part of executive compensation is a standard practice across the biotechnology and pharmaceutical industries, similar to companies like Biogen or Amgen, which utilize similar equity incentive structures to align management interests with shareholder value.
• The 'sell to cover' mechanism for tax withholding on RSU vesting is also a widely adopted and standard procedure for equity compensation in public companies, ensuring compliance with tax obligations without requiring a discretionary sale by the insider.

Corporate Governance

Related Party Transactions

• Acquisition of shares through the Athira Pharma, Inc. 2020 Employee Stock Purchase Plan (ESPP) and vesting of Restricted Stock Units (RSUs) are transactions between the company and an officer, which are standard compensation practices.

Stakeholder Impact

• Shareholders may view the Chief Scientific Officer's continued participation in equity compensation plans and increased beneficial ownership as a positive sign of alignment with company performance and long-term strategy.
• Employees participating in the ESPP benefit from the ability to purchase company stock at a discount.

Next Steps

• The remaining 36,667 Restricted Stock Units are scheduled to vest on December 31, 2025, subject to the reporting person continuing to be a Service Provider.

Key Dates

Keywords

Athira Pharma, ATHA, Kevin Church, Form 4, SEC filing, insider transaction, beneficial ownership, employee stock purchase plan, ESPP, restricted stock units, RSU, equity compensation, Chief Scientific Officer